Syneos Health, Inc.(SYNH) Stock Research - Grey Stern Research

Syneos Health, Inc. (SYNH) Stock Analysis

$42.98 (0.02%)

SYNH Financial Performance


Use the table below to view Syneos Health, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2023

Metric Value Ranking among Peers
Price $42.98 -
52 Week Low $22.89 -
52 Week High $52.23 -
Market Cap $4.5 Billion 9/14
Gross Margin 22% 13/14
Profit Margin 0% 10/14
EBITDA margin 8% 11/14
Q2 - 2023 Revenue $1.4 Billion 4/14
Q2 - 2023 Earnings $793,000 10/14
Q2 - 2023 Free Cash Flow -$51.6 13/14
Trailing 4 Quarters Revenue $5.4 Billion 4/14
Trailing 4 Quarters Earnings $71.2 Million 8/14
Quarterly Earnings Growth -99% 13/14
Annual Earnings Growth -67% 11/14
Quarterly Revenue Growth 0% 10/14
Annual Revenue Growth 1% 7/14
Cash On Hand $82.2 Million 12/14
Short Term Debt $68.3 Million 6/14
Long Term Debt $2.8 Billion 4/14

Syneos Health, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Syneos Health, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 62.59 3/14
PS 0.82 14/14
PB 1.28 12/14
PC 54.25 2/14
Liabilities to Equity 1.31 5/14
ROA 0.01 9/14
ROE 0.02 10/14
Current Ratio 1.76 9/14
Quick Ratio 0.02 13/14
Long Term Debt to Equity 0.81 4/14
Debt to Equity 0.83 4/14
Burn Rate 0.64 11/14
Cash to Cap 0.02 12/14
CCR -65.12 14/14
EV to EBITDA 64.31 4/14
EV to Revenue 1.34 14/14

Company Details

Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development. This segment also provides individual services, including product development and regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health, clinical trial diversity, biometric, and regulatory affair services. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication services; and consulting services to the pharmaceutical, biotechnology, and healthcare industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.

CEO: Mr. Alistair Macdonald

Website: https://www.syneoshealth.com

Address: 1030 Sync Street Morrisville, NORTH CAROLINA

Exchange: NASDAQ Global Select

Industry: Diagnostics & Research

Syneos Health, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Syneos Health, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Qiagen N.V. QGEN $10.5 Billion
RadNet, Inc. RDNT $4.7 Billion
Laboratory Corporation of America Holdings LH $20.3 Billion
IQVIA Holdings Inc. IQV $37.3 Billion
Charles River Laboratories International, Inc. CRL $8.6 Billion
Mettler-Toledo International Inc. MTD $28.0 Billion
ICON Public Limited Company ICLR $16.8 Billion
Medpace Holdings, Inc. MEDP $10.7 Billion
Myriad Genetics, Inc. MYGN $1.1 Billion
Aclaris Therapeutics, Inc. ACRS $278.2 Million
Neogen Corporation NEOG $2.6 Billion
Sotera Health Company SHC $3.9 Billion
Olink Holding AB (publ) OLK $3.2 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
SYNH Income Statements
Quarter Year Revenue Earnings
Q2 2023 $ 1.4 Billion $793,000
Q1 2023 $ 1.4 Billion -$72.1 Million
Q4 2022 $ 1.4 Billion $55.5 Million
Q3 2022 $ 1.3 Billion $87.0 Million
Q2 2022 $ 1.4 Billion $77.7 Million
Q1 2022 $ 1.3 Billion $46.2 Million
Q4 2021 $ 1.4 Billion $76.0 Million
Q3 2021 $ 1.3 Billion $78.2 Million

View All

SYNH Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2023 $82.2 Million $8.1 Billion $2.9 Billion $3.5 Billion
Q1 2023 $111.1 Million $8.1 Billion $2.9 Billion $3.5 Billion
Q4 2022 $112.0 Million $8.2 Billion $2.9 Billion $3.5 Billion
Q3 2022 $170.1 Million $8.2 Billion $3.0 Billion $3.4 Billion
Q2 2022 $106.0 Million $8.2 Billion $3.1 Billion $3.3 Billion
Q1 2022 $119.2 Million $8.3 Billion $3.2 Billion $3.3 Billion
Q4 2021 $106.5 Million $8.2 Billion $3.1 Billion $3.4 Billion
Q3 2021 $122.4 Million $8.2 Billion $3.2 Billion $3.3 Billion

View All

SYNH Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2023 -$51.6 Million -$18.0 Million -$28.8 Million
Q1 2023 $2.9 Million -$27.5 Million -$949,000
Q4 2022 $100.2 Million -$23.6 Million -$58.1 Million
Q3 2022 $110.5 Million -$21.9 Million $64.1 Million
Q2 2022 $75.5 Million -$24.4 Million -$13.2 Million
Q1 2022 $47.4 Million -$23.5 Million $12.7 Million
Q4 2021 $159.1 Million -$26.9 Million -$16.1 Million
Q3 2021 $40.9 Million -$7.6 Million -$138.6 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions